BLU-945 Plus Osimertinib Has Favorable Tolerability, Warrants Further Development in EGFR+ NSCLC

BLU-945 alone or in combination with osimertinib demonstrated early signals of clinical activity and was well tolerated in heavily pretreated patients with EGFR-mutant non–small cell lung cancer.

Related Keywords

Texas ,United States ,Yasiry Elamin ,Bristol Myers Squibb Medarex ,Spectrum Pharmaceuticals ,University Of Texas Md Anderson Cancer ,Division Of Cancer Medicine ,Astrazeneca ,Neck Medical Oncology ,Cancer Medicine ,Bayesian Optimal Interval ,Turning Point ,Blueprint Medicines ,Elevation Oncology ,Precision Therapeutics ,Blu 945 Alone Or In Combination With Osimertinib ,Heavily Pretreated Patients With Egfr Mutant Non Small Cell Lung Cancer ,Symphony Trial ,Nct04862780 ,D ,The University Of Texas Md Anderson Cancer ,